Relmada Therapeutics, INC

Relmada Therapeutics announced the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer to lead corporate strategy and business development.

Relmada Therapeutics stockholders approved an increase in authorized common stock to 200 million shares at the 2026 Annual Meeting.

Relmada Therapeutics announced positive 12-month Phase 2 data for NDV-01 in bladder cancer, a $160 million PIPE financing, and plans to initiate Phase 3 trials in mid-2026.

Relmada Therapeutics, Inc. announced amended employment agreements for its executive officers, including salary increases and revised severance packages, effective January 1, 2026.

Relmada Therapeutics announced its third-quarter 2025 financial results, highlighted by positive 9-month data for its NDV-01 bladder cancer therapy and FDA alignment on Phase 3 trial designs, alongside a $100 million capital raise.

Relmada Therapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expected to raise approximately $100 million in gross proceeds.

Relmada Therapeutics reports significant progress in its clinical pipeline with NDV-01 and sepranolone, bolstered by a substantial capital raise, while navigating operational expenses.

Relmada Therapeutics reports a strategic pipeline overhaul, including two program terminations and the acquisition of two new drug candidates, alongside a significant $94 million capital raise to fund operations for the next 12 months.

Relmada Therapeutics reports a reduced net loss in Q2 2025, driven by strategic pipeline changes including new acquisitions and program terminations, but faces significant liquidity challenges and a Nasdaq compliance extension.

Relmada Therapeutics reports a net loss for Q1 2025 and provides updates on its strategic review, pipeline diversification, and key upcoming milestones.

Relmada Therapeutics reported its Q3 2024 financial results, highlighting ongoing clinical trials and a net loss, while also expressing substantial doubt about its ability to continue as a going concern.

Relmada Therapeutics reported a net loss of $39.6 million for the first six months of 2024, while continuing to advance its clinical programs for esmethadone and psilocybin.

Relmada Therapeutics, Inc. has undergone a significant strategic shift, terminating prior drug programs to focus on two new clinical-stage candidates, NDV-01 and sepranolone, while securing substantial new financing.

Relmada Therapeutics' 10-K filing reveals a strategic shift towards new drug candidates after disappointing trial results, emphasizing pipeline diversification and cost-effective development.

Relmada Therapeutics, a clinical-stage biotech company, reported its 2023 annual results, highlighting progress in its esmethadone and psilocybin programs, while also noting significant financial losses.

RELMADA THERAPEUTICS CEO Sergio Traversa acquired 27,500 shares of common stock and was granted 1.2 million Stock Appreciation Rights.

RELMADA Therapeutics' Chief Financial Officer, Maged Shenouda, acquired 11,665 common shares and was granted 828,000 stock appreciation rights.

RELMADA Therapeutics officer Chuck Ence was granted 828,000 stock appreciation rights with a $4.06 exercise price, vesting quarterly from March 2026.

RELMADA Therapeutics Director Fabiana Fedeli acquired 164,000 Stock Appreciation Rights with an exercise price of $4.06, vesting quarterly starting March 2026.

RELMADA Therapeutics Director John Glasspool was granted 164,000 Stock Appreciation Rights with an exercise price of $4.06, vesting quarterly starting March 2026.

RELMADA THERAPEUTICS, INC. COO and Director Paul Edward Kelly was granted 828,000 stock appreciation rights with an exercise price of $4.06, vesting quarterly starting March 2026.

Relmada Therapeutics is seeking shareholder approval to increase authorized shares and equity incentives following a strategic turnaround and $100 million capital raise.

Relmada Therapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 23, 2025, with proposals including the election of a Class I director, ratification of the accounting firm, and an amendment to the equity incentive plan.

Relmada Therapeutics is shifting its focus to acquiring and advancing new therapeutic candidates after a Phase 3 trial for esmethadone (REL-1017) showed it was unlikely to meet its primary endpoint.

Relmada Therapeutics has scheduled its 2024 Annual Meeting for May 24, 2024, and is providing proxy materials to stockholders.

Relmada Therapeutics is asking stockholders to approve an amendment to its 2021 Equity Incentive Plan to increase the number of shares available for issuance by 4.5 million, as the company progresses with its REL-1017 Phase 3 program and a new metabolic disease program.

Venrock Healthcare Capital Partners and affiliates have reported a 6.2% beneficial ownership stake in Relmada Therapeutics, Inc.

Adage Capital Management, L.P. and its affiliates have reported beneficial ownership of 4,763,158 shares, representing 4.54% of the outstanding common stock of Relmada Therapeutics, Inc.

Commodore Capital LP, along with affiliated entities and individuals, has reported beneficial ownership of 5,505,527 shares, representing 5.1% of Relmada Therapeutics, Inc.'s common stock.

Squadron Master Fund LP and related entities have disclosed a 9.99% beneficial ownership stake in RELMADA THERAPEUTICS, INC., totaling 7,395,510 shares.

Spruce Street Capital LP and its co-managing members have reported a 5.57% beneficial ownership stake in Relmada Therapeutics, Inc. common stock.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.82% beneficial ownership in Relmada Therapeutics, Inc. common stock.